Nosocomial bloodstream infections in HIV-infected patients: attributable mortality and extension of hospital stay.

A 3-year prospective matched case-control study was performed to investigate the potential risk factors, prognostic indicators, extension of hospital stay, and attributable mortality of nosocomial bloodstream infections in HIV-infected patients. Matching variables were: age, gender, number of circulating CD4+ T lymphocytes, cause of hospital admission, hospitalization in the same ward within the 6 weeks of diagnosis of the case, and length of stay before the day of infection in the case. Eighty-four cases and 168 matched controls were studied. Nosocomial bloodstream infections complicated about 3 of 1000 hospital days per patient in the study period. With step-wise logistic regression analysis, the most important predictors for developing nosocomial bloodstream infections were: increasing value of Acute Physiology and Chronic Health Evaluation (APACHE II) score (p = .001) and use of central venous catheter (CVC) (p = .002). The excess of hospital stay attributable to nosocomial bloodstream infections was 17 days. The crude mortality rate was 43%. The attributable mortality rate was estimated to be 27% (95% confidence interval [CI] = 13%-48%). The estimated risk ratio for death was 3.91 (95% CI = 2.06-7.44). Multivariate analysis identified two prognostic indicators that were significantly associated with unfavorable outcome of bloodstream infections: number of circulating CD4+ T cells <100/mm3 (p = .002) and APACHE II score >15 (p = .01). Nosocomial bloodstream infections are more common in patients with advanced HIV disease. Important cofactors are high APACHE II score and use of CVC. These infections can cause an excess mortality and significantly prolong the hospital stay of HIV-infected patients.

[1]  D. Pittet,et al.  Nosocomial bloodstream infections. Secular trends in rates, mortality, and contribution to total hospital deaths. , 1995, Archives of internal medicine.

[2]  E. Tacconelli,et al.  The impact of bacteraemia on HIV infection. Nine years experience in a large Italian university hospital. , 1995, The Journal of infection.

[3]  B. Gazzard,et al.  Central venous line infections in AIDS. , 1997, The Journal of infection.

[4]  G. Samsa,et al.  Nosocomial infection rate as a function of human immunodeficiency virus type 1 status in hemophiliacs. , 1991, The American journal of medicine.

[5]  K. Mayer,et al.  Opportunistic candidal infections in patients infected with human immunodeficiency virus: prevention issues and priorities. , 1995, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[6]  M. Jacobson,et al.  Human immunodeficiency virus disease-related neutropenia and the risk of hospitalization for bacterial infection. , 1997, Archives of internal medicine.

[7]  D. Shanson,et al.  Septicaemia in patients with and without AIDS at Westminster Hospital, London. , 1993, The Journal of infection.

[8]  R. Spengler,et al.  Hospital costs and mortality attributed to nosocomial bacteremias. , 1978, JAMA.

[9]  J M Hughes,et al.  CDC definitions for nosocomial infections, 1988. , 1988, American journal of infection control.

[10]  R. Gaynes,et al.  Nosocomial infection rates in adult and pediatric intensive care units in the United States. National Nosocomial Infections Surveillance System. , 1991, The American journal of medicine.

[11]  P. Massip,et al.  Impact of protease inhibitors on AIDS‐defining events and hospitalizations in 10 French AIDS reference centres , 1997, AIDS.

[12]  E. Tacconelli,et al.  Predictors of Staphylococcus aureus pneumonia associated with human immunodeficiency virus infection. , 1996, Respiratory medicine.

[13]  J. Phair,et al.  Indwelling central venous catheter infections in patients with acquired immune deficiency syndrome. , 1990, Journal of acquired immune deficiency syndromes.

[14]  D. Warrell,et al.  Life-threatening bacteraemia in HIV-1 seropositive adults admitted to hospital in Nairobi, Kenya , 1990, The Lancet.

[15]  F. Meunier,et al.  Candidemia in immunocompromised patients. , 1992, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[16]  C. Pradier,et al.  [Community-acquired and nosocomial septicemias in patients with human immunodeficiency virus infection]. , 1996, Presse medicale.

[17]  D. Fife,et al.  Cumulative AIDS incidence and altered mortality from bacterial infections. , 1990, AIDS research and human retroviruses.

[18]  L. Pagano,et al.  Bacteremia in patients with hematological malignancies. Analysis of risk factors, etiological agents and prognostic indicators. , 1997, Haematologica.

[19]  L. Hirschhorn,et al.  Nosocomial Colonization and Infection in Persons Infected With Human Immunodeficiency Virus , 1996, Infection Control &#x0026; Hospital Epidemiology.

[20]  A. Pablos-Mendez,et al.  HighStaphylococcus aureus nasal carriage rate in patients with acquired immunodeficiency syndrome or AIDS-related complex , 1990 .

[21]  R. Cauda,et al.  Role of polymorphonuclear leukocytes in infection by retroviruses with emphasis on the human immunodeficiency virus. , 1990, Viral immunology.

[22]  W. Knaus,et al.  APACHE II: a severity of disease classification system. , 1985 .

[23]  Didier Pittet,et al.  Nosocomial bloodstream infection in critically ill patients. Excess length of stay, extra costs, and attributable mortality. , 1994, JAMA.

[24]  M. A. Martin,et al.  Coagulase-negative staphylococcal bacteremia. Mortality and hospital stay. , 1989, Annals of internal medicine.

[25]  D. Pittet,et al.  Microbiological factors influencing the outcome of nosocomial bloodstream infections: a 6-year validated, population-based model. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.